Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/21/2016 |
| Start Date: | May 2005 |
| End Date: | April 2008 |
Evaluation of Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotic Medications
Because ziprasidone has not been extensively studied and is not widely accepted in the
severely mentally ill in State hospitals this study aims to demonstrate its effectiveness
and relative lack of side effects. 75 patients with schizophrenia or schizoaffective
disorder who need a change of medication because of ineffectiveness or side effects will be
changed to ziprasidone and followed with detailed assessments for eight weeks.
The hypothesis is that they will improve and have fewer side effects.
severely mentally ill in State hospitals this study aims to demonstrate its effectiveness
and relative lack of side effects. 75 patients with schizophrenia or schizoaffective
disorder who need a change of medication because of ineffectiveness or side effects will be
changed to ziprasidone and followed with detailed assessments for eight weeks.
The hypothesis is that they will improve and have fewer side effects.
Ziprasidone has been found in studies and practice to be efficacious and tolerated well but
has not been well studied or well accepted in the very severely ill in State Hospitals. This
study aims to fill that gap by examining 75 patients with schizophrenia or schizoaffective
disorder who require a change of medication because of poor response or unacceptable side
effects.
After signing consent and having a baseline assessment they will, if necessary, be reduced
to one antipsychotic then started on ziprasidone, increasing to 160mg the second day. The
one antipsychotic they had been on will be reduced over a week and stopped. The ziprasidone
can be increased to 240mg after three weeks if necessary.
The study will last eight weeks with efficacy assessed by Clinical Global Impressions (CGI),
Positive and Negative Syndrome Scale (PANSS) every two weeks and Brief Assessment of
Cognition, Calgary Depression Scale for Schizophrenia, Personal Evaluation of Transitions in
Treatment and Medical Outcomes Study Cognitive Questions at the beginning and end. Side
effects will be measured by movement disorder scales (Simpson-Angus scale for Parkinsonism
(SANRS), Abnormal Involuntary Movement Scale (AIMS) and Barnes Akathisia Scale (BAS)), ECG
and weight and blood metabolic measures.
The hypothesis is that ziprasidone will be generally effective and that side effects
especially metabolic indices will be reduced.
has not been well studied or well accepted in the very severely ill in State Hospitals. This
study aims to fill that gap by examining 75 patients with schizophrenia or schizoaffective
disorder who require a change of medication because of poor response or unacceptable side
effects.
After signing consent and having a baseline assessment they will, if necessary, be reduced
to one antipsychotic then started on ziprasidone, increasing to 160mg the second day. The
one antipsychotic they had been on will be reduced over a week and stopped. The ziprasidone
can be increased to 240mg after three weeks if necessary.
The study will last eight weeks with efficacy assessed by Clinical Global Impressions (CGI),
Positive and Negative Syndrome Scale (PANSS) every two weeks and Brief Assessment of
Cognition, Calgary Depression Scale for Schizophrenia, Personal Evaluation of Transitions in
Treatment and Medical Outcomes Study Cognitive Questions at the beginning and end. Side
effects will be measured by movement disorder scales (Simpson-Angus scale for Parkinsonism
(SANRS), Abnormal Involuntary Movement Scale (AIMS) and Barnes Akathisia Scale (BAS)), ECG
and weight and blood metabolic measures.
The hypothesis is that ziprasidone will be generally effective and that side effects
especially metabolic indices will be reduced.
Inclusion Criteria:
- Schizophrenia or schizoaffective
- Capacity to give consent
- Stable, on the same medication for a month but only partial response or with
unacceptable side effects 18-65 years of age
Exclusion Criteria:
- Repeated non-compliance
- Current depot medication
- Active medical conditions
- QTc >500msec
- Previous non-response
- Previous treatment with ziprasidone
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials